Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | CTSG | P08311 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1974539 | 1.00 | CYP2D6 (0.42) | CYP2D6ELANECTSGKMT2AALDH1A1 | |
| SCHEMBL1976076 | 1.00 | CYP2D6 (0.42) | CYP2D6ELANECTSGKMT2AALDH1A1 | |
| SCHEMBL1691950 | 0.93 | CYP2D6 (0.41) | CYP2D6ELANECTSGKMT2AALDH1A1 | |
| SCHEMBL1972893 | 0.90 | CYP2D6 (0.34) | CYP2D6ELANECTSGKMT2A | |
| SCHEMBL1819283 | 0.90 | CYP2D6 (0.34) | CYP2D6ELANECTSGKMT2A | |
| SCHEMBL1974127 | 0.90 | CYP2D6 (0.34) | CYP2D6ELANECTSGKMT2A | |
| SCHEMBL1976892 | 0.88 | SMN1; SMN2 (0.40) | CYP2D6KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL1975655 | 0.88 | SMN1; SMN2 (0.40) | CYP2D6KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL1820167 | 0.88 | SMN1; SMN2 (0.40) | CYP2D6KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL1976683 | 0.86 | NR1H2 (0.33) | CYP2D6ELANECTSG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2315748-B1 | PROCESSES FOR THE PREPARATION OF 4-OXO-OCTAHYDRO-INDOLE-1-CARBOCYLIC ACID METHYL ESTER AND DERIVATIVES THEREOF | NOVARTIS AG (CH) | 2015-06-24 | — | — | EP | disclosed |
| US-8084487-B2 | Processes for the preparation of 4-oxo-octahydro-indole-1-carbocyclic acid methyl ester and derivatives thereof | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20110144352-A1 | PROCESSES FOR THE PREPARATION OF 4-OXO-OCTAHYDRO-INDOLE-1-CARBOCYCLIC ACID METHYL ESTER AND DERIVATIVES THEREOF | NOVARTIS AG (CH) | 2011-06-16 | — | — | US | disclosed |
| EP-2315748-A1 | PROCESSES FOR THE PREPARATION OF 4-OXO-OCTAHYDRO-INDOLE-1-CARBOCYLIC ACID METHYL ESTER AND DERIVATIVES THEREOF | Novartis AG (CH) | 2011-05-04 | — | — | EP | disclosed |
| WO-2010018154-A1 | PROCESSES FOR THE PREPARATION OF 4-OXO-OCTAHYDRO-INDOLE-1-CARBOCYLIC ACID METHYL ESTER AND DERIVATIVES THEREOF | NOVARTIS AG (CH) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144352-A1 | PROCESSES FOR THE PREPARATION OF 4-OXO-OCTAHYDRO-INDOLE-1-CARBOCYCLIC ACID METHYL ESTER AND DERIVATIVES THEREOF | KMO, IDO1, ALKBH3 | CYP2D6 73/4885ELANE 4304/4885CTSG 2096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.